For IBS-D (diarrhea-predominant), common after COVID infection, options include: Rifaximin (550mg three times daily for 14 days) shows moderate evidence of efficacy, with retreatment possible for recurrent symptoms
Patients who qualify may receive injection technique guidance, individualized dosing instructions, treatment education, and follow-up support
The evidence for ghk-cu topical should be weighed by study type, human relevance, route, product quality, and the limits of what has actually been demonstrated
Storage Reference Chart Proper storage preserves potency and maximizes your investment
Not quitebut theyre a powerful addition to a smart, long-term approach